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Introduction
The European Academy of Allergy and Clinical Immu-
nology (EAACI) supports three official journals: Allergy, 
Paediatric Allergy and Immunology as well as Clinical 
and Translational Allergy. The major goals of EAACI 
include (i) supporting health promotion in which the pre-
vention and control of allergy plays a critical role and (ii) 
disseminating the knowledge of allergy to all stakeholders 
including the EAACI Junior Members. The EAACI jour-
nals reported advances in allergy in 2017 [1, 2] and 2018 
[3]. This paper summarizes the achievements of 2018 in 
atopic dermatitis and urticaria. The position papers and 
EAACI/WAO/GA2LEN guidelines are summarized.
Atopic dermatitis
Mechanisms
Atopic dermatitis (AD), commonly known as eczema, is 
a chronic skin disorder associated with skin barrier dys-
function that is characterized by dry, itchy skin (pruritus). 
Interleukin-31 (IL-31) secreted by T-helper 2  (TH2) cells 
induces the itchy symptoms. The role of IL-31 in the 
pathogenesis of AD and novel therapeutic strategies tar-
geting its receptor have been recently reviewed [4].
AD patients have an altered skin microbiome com-
position characterized by an increased colonization of 
Staphylococcus aureus (S. aureus) which is associated 
with disease severity. In addition, AD patients have a 
reduced expression of toll-like receptor-2 (TLR2) recep-
tors in Langerhans cells (LC) and inflammatory dendritic 
epidermal cells (IDEC) compared to healthy controls [5]. 
Ex vivo human skin models were treated with the TLR2 
ligand Pam3Cys, a mimic of S. aureus. In contrast to 
healthy skin, LC and IDEC lacked maturation and had a 
strong spontaneous migratory activity. The supernatant 
of AD skin showed significantly reduced levels of IL-6 
and IL-10 and an overexpression of IL-18.
A novel mechanism involved in epidermal barrier 
dysfunction was recently reported in a mouse model 
of allergic inflammation and in AD patients [6]. It was 
found that IL-24 downregulates filaggrin expression and 
is produced in keratinocytes by the stimulation of IL-13 
in a periostin-dependent manner. Elevated levels of IL-24 
and activated STAT3 were found in the epidermis of the 
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The role of the pruritogenic mediator endothelin-1 (ET-
1) in the pathogenesis of AD was recently investigated in 
mouse bone marrow-derived dendritic cells (BMDCs) 
[7]. ET-1 was significantly upregulated in the epidermis 
of AD patients and stimulated the production of Th1 and 
Th17 cytokines from BMDCs in a concentration-depend-
ent manner. This switch to a Th17/Th1 response may 
contribute to the chronic lesions in AD patients.
Studies in a human AD-like mouse model revealed 
novel mechanistic insights that support a link between 
cell infiltration of the hypodermis to local mast cell acti-
vation and elevated levels of sphingosine-1-phosphate 
(S1P) after antigen exposure [8]. Neuromedin U (NMU) 
released from keratinocytes induces the degranulation of 
mast cells via pertussis toxin-sensitive G protein-coupled 
receptors [9].
Exposure to air pollution aggravates the  symptoms 
of AD in children in the population studies. Variabil-
ity in the individual patient’s response from individual 
susceptibility needs to be explored. In 89 children aged 
0–6 years with AD, daily manifestation of symptoms was 
recorded for an average of 257  days and confronted to 
pollution levels [10]. In the overall analysis, ozone, par-
ticulate matter < 10  μm  (PM10),  NO2,  SO2, and CO had 
a significantly positive association, whereas temperature 
and relative humidity were negatively associated with AD 
symptoms. However, responses of AD children to air pol-
lution and weather variables were inconsistent among 
individuals.
Epidemiologic studies
Earlier studies have shown an association between the 
month of birth and the severity of atopic dermatitis. In 
one study, Armenian children were investigated for the 
severity of their eczema in relation to the month of birth. 
It was found that children born in the winter had more 
severe eczema. The authors hypothesized, in relation 
to earlier findings, that the severity of eczema could be 
related to an  early exposure to common environmental 
allergens [11].
Data of the epidemiology of atopic dermatitis were 
collected in an online survey from patients in the US, 
Canada, France Germany, Italy, Spain, UK, and Japan 
[12]. The respondents were characterized and selected if 
they met the UK Working Party/ISAAC criteria and had 
been previously diagnosed by a physician. There was a 
decreased prevalence of AD with age and, except for the 
US, a higher prevalence among women. Only a small por-
tion suffered severe AD across all regions. The severity of 
AD varied according to the different assessment scales 
used (Patient-Oriented SCORAD, Patient-Orientated 
Eczema Measure, and Patient Global Assessment).
The plan for the Preventing Atopic Dermatitis and 
ALLergies (PreventADALL) in children study has been 
recently reported [13]. Its main objectives are the preven-
tion of allergic diseases by assessing early-life risk factors, 
including microbial diversity, diet, lifestyle, and gene–
environment interactions, using simple cost-efficient 
strategies. Children born by cesarean section and by 
assisted birth are at an increased risk of developing flex-
ural eczema in childhood/early adulthood [14].
There are limited and conflicting reports on the long-
term clinical course of AD. A systematic review and 
meta-analysis of 2080 references and 7 birth cohort stud-
ies with a total of 13,515 participants indicated that there 
is a similar prevalence of AD in childhood and adoles-
cence [15]. Undergoing thymectomy in early childhood 
was associated with a reduced risk of AD but was only 
statistically significant in a model where time-dependent 
changes were not included [16].
Severity scores
Reliability and validity of the AD Symptom Score (ADSS) 
were  studied in 307 children and adolescents with AD 
[17]. Parents or caregivers were asked to record daily 
symptoms of the patients (itching, sleep disturbance, ery-
thema, dryness, oozing, and edema) using a scale of 0–4. 
The ADSS was found be a useful tool for the self-assess-
ment of skin symptoms in children with AD.
A recent study has validated the use of patient-reported 
AD severity assessment using a single question with a 
simple scoring system of mild, moderate and severe [18]. 
The responses from 265 adult patients significantly cor-
related with other outcome measures, including oSCO-
RAD, SCORAD, EASI, BSA, NRS-itch, POEM, and 
DLQI, and were further confirmed by a dermatologist.
Multimorbidities
The association between AD and cardio-metabolic risk 
factors is not fully understood, partly due to the lack of 
validated questionnaire-based methods to identify adults 
with AD. In an attempt to investigate the association of 
cardio-metabolic risk factors in AD patients, data col-
lected from 9656 Danish adults were analyzed using three 
different cardiovascular risk questionnaires [19]. There 
was a large discrepancy in the results from each question-
naire and so a definite conclusion could not be reached. 
These results highlight the need for clinical diagnosis of 
AD by a dermatologist and the fact that responses from 
questionnaires should be carefully interpreted.
In a nationwide, population-based cohort study (Tai-
wan’s National Health Insurance Research Database), 
the association between obstructive sleep apnoea (OSA) 
and AD was sought in 120,736 children [20]. This study 
revealed an increased risk of obstructive sleep apnoea 
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in children with AD. Therefore, comprehensive evalua-
tion and aggressive risk reduction for obstructive sleep 
apnoea are recommended in these patients.
AD can significantly impact quality-of-life to the point 
that it can affect mental health. Data collected from the 
Danish health registry and a population-based question-
naire indicated that AD patients had an increased risk of 
mild anxiety, depression and suicidal ideation compared 
to non-AD subjects but did not result in psychiatric hos-
pitalization or suicide [21]. Early antihistamine exposure 
for the treatment of AD was associated with increased 
attention-deficit/hyperactivity disorder symptoms in 
children aged 6–12 years. The study questionnaire asked 
parents whether their child had used systemic antihista-
mines to treat AD but did not distinguish between sedat-
ing and non-sedating H1-antihistamines. The authors 
noted that there is a need to further investigate the role of 
sleeping problems and its treatment with (sedating) anti-
histamines in young children concerning early-life devel-
opment and the potential risk for ADHD in children with 
AD [22].
Prevention and treatment
The protective effect of the Bacillus Calmette–Guerin 
(BCG) vaccination to reduce the risk of allergic diseases, 
including AD, is unclear. A recent study from the Danish 
Calmette (2012–2015) found that the clinical outcome of 
the BCG vaccination differed for children with and with-
out atopic predisposition [23]. The cumulative incidence 
of AD was reduced by 16% in infants with an atopic pre-
disposition. Oral antigen administration in mice has a 
protective effect against AD by promoting the increased 
expression of genes involved in the regulation of Th2 
inflammatory responses and skin barrier function [24].
A randomized, double-blinded, placebo-controlled 
trial assessed the effects of melatonin administration on 
disease severity and sleep quality in 70 children with AD 
[25]. Overall, melatonin supplementation had beneficial 
effects on disease severity, serum total IgE levels, and on 
the Children’s Sleep Habits Questionnaire (CSHQ).
The efficacy of allergen-specific subcutaneous immu-
notherapy (SIT) as a curative treatment for atopic der-
matitis remains controversial. A murine model was 
established to investigate the clinical efficacy of SIT [26]. 
The DfE-treated NC/Nga mice showed clinical, histologi-
cal and immunological improvement with elevated levels 
of IL-10 producing Treg cells and NK cells.
The potential use of superoxide dismutase 3-trans-
ducer (SOD3) mesenchymal stem cells (MSCs), as a novel 
cell-based therapy for AD, was demonstrated in a mouse 
model of OVA-induced AD-like skin inflammation [27]. 
Mice with AD that received a subcutaneous administra-
tion of SOD3-MSCs showed an improvement of skin 
thickening and inflammation compared to control mice. 
The reduced skin inflammation was attributed to the 
inhibition of the histamine  H4 receptor, MAPK/NFkB 
activation and JAK/STAT signalling.
Maternal exposure to a farming environment protects 
newborns against allergic diseases including AD by mod-
ulating the neonatal TLR-Tregs-Th axis [28].
In cats and dogs, there are pathogenetic similarities 
with human AD. This  is often a difficult disease for ani-
mals and their owners [29].
Urticaria
Mechanisms and risk factors
Salt-dependent aquagenic urticaria is rare and has only 
ever been reported in adults, especially young women. 
Two cases of salt-dependent aquagenic urticaria have 
now been reported in children [30].
Two additional cases of cancer and chronic urticaria 
have also  been reported [31, 32]. The urticaria resolved 
once the tumour was removed. A review of 25 previous 
reports of chronic urticaria and malignancy raises the 
possibility that CU and malignancies are linked in some 
patients [3].
Exposure to phthalates increases the risk of acute urti-
caria in children [33].
A recent study in 49 Caucasian CSU patients found 
elevated levels of specific IgE against a mix of Staphy-
lococcus aureus enterotoxins (SEs) in 51% of patients 
compared to 33% in healthy controls [34]. Total serum 
IgE levels and CSU disease activity were correlated with 
Staphylococcus enterotoxin B-IgE (SEB-IgE) levels. These 
results suggest a role of SEs IgE antibodies in the patho-
genesis of CSU, in keeping with the current hypothesis of 
autoallergy being important in some patients.
CSU patients are known to have elevated levels of 
C-reactive protein (CRP) and it is a sensitive inflamma-
tory biomarker for the diagnosis and disease activity of 
CSU. In a retrospective study of 1253 CSU patients, 
higher levels of CRP were associated with autologous 
serum skin test positivity, arterial hypertension, urti-
caria activity, quality of life impairment, inflammatory 
and coagulation markers, and poor response to antihis-
tamines [35].
A systematic review assessed the relationship between 
vitamin D and CSU [36]. Fourteen studies  (1321 CSU 
cases and 6100 controls) were considered. Twelve stud-
ies showed statistically significant lower serum vitamin 
D levels in CSU patients than in the controls. Vitamin 
D deficiency was reported more commonly for CSU 
patients (34.3–89.7%) than for controls (0.0–68.9%) in 6 
studies. Seven showed disease improvement after high-
dosages of vitamin D supplementation. Well-designed 
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randomized placebo-controlled studies are needed to 
determine the cut-off levels of vitamin D for supplemen-
tation and treatment outcomes.
Epidemiologic studies
A physician-based online survey conducted in 5 Euro-
pean countries (United Kingdom, Germany, Italy, France, 
and Spain) assessed the annual diagnosed prevalence, 
disease characteristics, and treatment of CU (chronic 
inducible and spontaneous urticaria) and CSU in children 
[37]. Across the 5 European countries, the one-year diag-
nosed prevalence of CU and CSU in paediatric patients 
was 1.38% and 0.75%. This study showed a prevalence of 
CSU in children comparable to adults. Angioedema was 
reported in 6–14% of patients. A large proportion of CSU 
paediatric patients (40–60%) were treated with H1-anti-
histamines at approved doses and 16–51% received 
H1-antihistamines at higher doses. Approximately 1/3 
of paediatric CSU patients remained uncontrolled with 
H1-antihistamines at approved/higher doses.
A systematic review was carried out in children under 
12  years of age with CSU to assess interventions and 
comorbidities [38]. The systematic review included 9 
reports (633 children). Five comorbidities and laboratory 
anomalies were found to be associated with CSU: atopy 
(28.1%), positive autologous serum skin test (36.8%), thy-
roid anomalies (6.4%) and detectable antinuclear antigen 
(10.4%), seroprevalence for Helicobacter pylori (21.1%), 
low vitamin D level (69.1%), and psychiatric disorders 
(70.4%). Only one study allowed for comparison with a 
control group.
The ASSURE-CSU (ASsessment of the Economic 
and Humanistic Burden of Chronic Spontaneous/Idi-
opathic URticaria PatiEnts) study analyzed the socio-
economic burden of CSU. A recent post hoc analysis of 
the ASSURE-CSU study evaluated 673 patients with 
inadequately controlled CSU and revealed significant 
differences between patient- and physician-reported 
angioedema [39]. These were classified—according to 
the availability of medical records and patient-reported 
diagnosis—as  : Yes-angioedema (concordant) (40.3%), 
No-angioedema (concordant) (26.9%) and Misaligned 
(32.8%). The frequency of angioedema in CSU patients 
is under-recognized by physicians, even though it has 
significant impact on quality-of-life, work productivity 
and health care resource utilization. The international 
EAACI/GA2LEN/EDF/WAO methods report for the 
guidelines and recommendations for the management 
and diagnosis of angioedema has been recently revised 
[40].
OPuS-2 is a Phase 3 clinical study that investigated the 
efficacy and safety of avoralstat, a kallikrein inhibitor, 
on hereditary angioedema (HAE) caused by mutations 
in the SERP-ING1 gene that leads to a deficiency of the 
kallikrein inhibitor, C1 inhibitor (C1-INH) [41]. Unlike 
in the previous Phase 1 and Phase 2 clinical studies, the 
treatment efficacy with 500  mg avoralstat, 3 times daily 
for 12 weeks, could not be demonstrated. However, these 
patients experienced shortened angioedema episodes and 
improved QoL as assessed using the Angioedema Quality 
of Life Questionnaire (AE-QoL). In a separate study, the 
natural course of an oedematous attack in a patient with 
hereditary angioedema due to C1-INH deficiency was 
monitored for 96 h. The concentration of the C4a activa-
tion product significantly increased during the prodro-
mal period suggesting that C4a could potentially be used 
as a prognostic biomarker of an edematous attack [42]. A 
novel type of HAE with normal C1-INH levels has been 
identified as having a mutation in the plasminogen gene 
and is manifested as swelling of the face/lips and tongue 
[43].
Diagnosis and severity scores
The EAACI/GA2LEN/EDF/WAO guidelines for the defi-
nition, classification, diagnosis and management of urti-
caria have been recently revised and updated [44–46].
CSU disease activity is commonly measured using the 
urticaria activity scores UAS7 and  UAS7TD. The main dif-
ferences between the two is that in UAS7, symptoms are 
recorded daily whilst in  UAS7TD, symptoms are recorded 
twice a day, and that they use different wheal scoring sys-
tems. The two different versions showed similar results 
when assessing the severity of 130 CSU patients, suggest-
ing the preferential use of the simpler UAS7 scoring sys-
tem [47].
Multimorbidities
There are limited reports on the association between 
CU and systemic lupus erythematosus (SLE). The logis-
tic regression analysis of 2000–2011 claims data from the 
Taiwanese National Health Insurance Research Database 
of 2105 children suffering from SLE. It is indicated that 
there is an increased risk of developing acute urticaria 
and CU, particularly in female patients [48]. A compre-
hensive literature review indicated that chronic hepati-
tis B and C are not associated with CSU and so routine 
screening for these viral infections in CSU patients is not 
necessary [49].
Treatment
Bilastine is a  H1-antihistamine prescribed for the treat-
ment of CSU at a standard daily dose of 20  mg. Some 
patients may benefit from updosing to 40  mg and up 
to 80  mg for the most severe cases [50]. The X-ACT 
study is a clinical phase III to examine the effec-
tiveness of omalizumab for the treatment of CSU 
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patients with angioedema refractory to high doses of 
 H1-antihistamines. The reduction in angioedema symp-
toms when CSU patients were treated with 300  mg 
omalizumab significantly improved the QoL and psycho-
logical well-being as assessed by the Angioedema Quality 
of Life and the Dermatology Life Quality Index (DLQI) 
questionnaires [51].
Findings from the Icatibant Outcome Survey, a cohort 
observational study, showed that the effectiveness of Icat-
ibant for the treatment of hereditary angioedema attacks 
is not affected by body weight [52].
Two case reports of omalizumab being effective in 
normo-complementaemic urticarial vasculitis (UV) reo-
pens discussion about the pathogenesis of UV and its 
relationship with CSU [53]. CSU patients have elevated 
levels of IgE to tissue factor and thyroglobulin which 
are reduced in patients treated with CSU [54]. The IgE 
levels can be used as a prognostic marker for the thera-
peutic response of omalizumab. The IgE levels in CSU 
patients treated with omalizumab at baseline [55] and 
after 4  weeks of treatment [56] were significantly lower 
in non-responders compared to partial and complete 
responders.
Even though the administration of 300 mg omalizumab 
may be successful in the treatment of CSU patients who 
do not respond to antihistamines, it does not cure the 
disease and patients often relapse after the regimen is 
completed. The high cost of the drug has prompted The 
Italian Medical Agency to prohibit the administration of 
omalizumab beyond 1 year of treatment and so there is 
an urgent need for alternative therapies after 1  year. A 
study of 14 patients with complete response to omali-
zumab after 6  months (300  mg/month) demonstrated 
that half of the patients could be switched to a regimen of 
150 mg/month for an additional 4 months as an add-on 
treatment to second-generation antihistamines [57].
Serum sickness-like reaction was observed in a child 
using omalizumab for CSU [58], having previously been 
reported only in an adult. This is included as a warning in 
the summary of product characteristics.
Conclusion
Many important papers have been published in EAACI 
journals this year.
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